User profiles for P. Cipriani

Paola Cipriani

- Verified email at cc.univaq.it - Cited by 13209

paolo cipriani

- Verified email at hi.no - Cited by 1919

Beyond the joints, the extra-articular manifestations in rheumatoid arthritis

…, O Berardicurti, F Ursini, R Giacomelli, P Cipriani - Autoimmunity …, 2021 - Elsevier
Rheumatoid arthritis (RA) is an inflammatory disease typically affecting the joints, but the
systemic inflammatory process may involve other tissues and organs. Many extra-articular …

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in …

…, P Sarzi-Puttini, C Botsios, A Carletto, P Cipriani… - Autoimmunity …, 2012 - Elsevier
p < 0.046), concomitant DMARD treatment during anti-TNF therapy (p = 0.004), advanced age
at the start of anti-TNF treatment (p … than ETN (respectively p < 0.0001 and p = 0.023) were …

[HTML][HTML] The Role of IL-1β in the Bone Loss during Rheumatic Diseases

P Ruscitti, P Cipriani, F Carubbi, V Liakouli… - Mediators of …, 2015 - hindawi.com
Several inflammatory diseases have been associated with increased bone resorption and
fracture rates and different studies supported the relation between inflammatory cytokines and …

[HTML][HTML] Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and …

O Distler, A Del Rosso, R Giacomelli, P Cipriani… - Arthritis Research & …, 2002 - Springer
… In all groups including patients with pre-SSc, levels of VEGF were significantly higher than
in healthy controls (P < 0.001). This indicates that the increased levels of VEGF are both early …

[HTML][HTML] Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

…, P Cipriani, A Marrelli, PD Benedetto, P Ruscitti… - Arthritis research & …, 2013 - Springer
P < 0.05, comparison between the two treatment arms at the corresponding time point. …
P <0.01 and *P <0.05, comparison between the two treatment arms at the corresponding time …

Impairment of endothelial cell differentiation from bone marrow–derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis

P Cipriani, S Guiducci, I Miniati, M Cinelli… - Arthritis & …, 2007 - Wiley Online Library
Objective Systemic sclerosis (SSc) is a disorder characterized by vascular damage and
fibrosis of the skin and internal organs. Despite marked tissue hypoxia, there is no evidence of …

Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?

A Marrelli, P Cipriani, V Liakouli, F Carubbi… - Autoimmunity …, 2011 - Elsevier
Angiogenesis is the formation of new blood vessels from existing vessels. During RA new
blood vessels can maintain the chronic inflammatory state by transporting inflammatory cells to …

Molecular epidemiology of Anisakis and anisakiasis: an ecological and evolutionary road map

S Mattiucci, P Cipriani, A Levsen, M Paoletti… - Advances in …, 2018 - Elsevier
This review addresses the biodiversity, biology, distribution, ecology, epidemiology, and
consumer health significance of the so far known species of Anisakis, both in their natural hosts …

Genetic and Morphological Approaches Distinguish the Three Sibling Species of the Anisakis simplex Species Complex, with a Species Designation as Anisakis berlandi n. sp …

S Mattiucci, P Cipriani, SC Webb… - The Journal of …, 2014 - meridian.allenpress.com
Numerous specimens of the 3 sibling species of the Anisakis simplex species complex (A.
pegreffii, A. simplex (senso stricto)), and A. simplex sp. C) recovered from cetacean species …

[HTML][HTML] Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

P Ruscitti, P Cipriani, F Masedu, D Iacono, F Ciccia… - BMC medicine, 2016 - Springer
… a point biserial correlation with the corresponding P values. An ordered logistic risk model, …
(P < 0.05). The overall model fitting was estimated using a likelihood ratio test (LR = 91.55, P